JW Pharma Starts Phase 2 Clinical Trial for Gout Treatment

Lee Han-soo reporting for Korea Biomedical Review notes that Korean biopharmaceutical venture JW Pharmaceutical has received approval from the Korean Ministry of Food and Drug Safety to move forward on a Phase 2b clinical trial for URC102, a gout treatment. The drug...

Pin It on Pinterest